Zucara Therapeutics' Positive Proof-of-Concept Data Secures Continued Funding Ahead of Planned Phase 2 Clinical Trial of ZT-01

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Zucara Therapeutics, a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, recently announced that its positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01, which is expected to begin in Q1 2023.

Zucara is an OBIO® member and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Oncoustics AI and UHN Awarded OBIO® Early Adopter Health Network Grant to Trial Point of Care Liver Assessment Solutions in Clinic
Next

Oncoustics AI and UHN Awarded OBIO® Early Adopter Health Network Grant to Trial Point of Care Liver Assessment Solutions in Clinic